EFFICACY OF COLISTIN AND NON-COLISTIN MONOTHERAPIES IN MULTI-DRUG RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA/SEPSIS
Tarih
2014Yazar
Karabay, OguzBatirel, Ayse
Balkan, Ilker Inanc
Agalar, Canan
Akalin, Serife
Alici, Ozlem
Alp, Emine
Alta, F. Aybala
Altin, N.
Arslan, Ferhat
Aslan, Turan
Bekiroglu, Nural
Cesur, Salim
Celik, Aygul Dogan
Dogan, Mustafa
Durdu, Bulent
Duygu, Fazilet
Engin, Aynur
Engin, Derya Ozturk
Gonen, Ibak
Guclui, Ertugrul
Guven, Tumer
Hatipoglu, Cigdem Ataman
Hosoglu, Salih
Karahocagil, Mustafa
Kilic, Aysegul Ulu
Ormen, Bahar
Ozdemir, Davut
Ozer, Serdal
Oztoprak, Nefise
Sezak, Nurbanu
Turhan, Vedat
Turker, N.
Yilmaz, Hava
Üst veri
Tüm öğe kaydını gösterÖzet
Objective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with MDR-AB from 27 tertiary-referral hospitals between January 2009 and December 2012 were included. Patients' data that were on either colistin monotherapy (CM) or non-colistin monotherapy (NCM) were compared. Mortality on Day 14 was the primary endpoint, whereas microbiological eradication and clinical outcome were the secondary ones. Results: Eighty-four cases were included in the study with 36 being in the CM group and 48 in the NCM group. Thirty-eight (452%) cases were male and the mean age was 602 years. The mean durations of pre-MDR-AB hospital stay and intensive care unit stay were 25.8 days and 20.9 days, respectively. All of the cases had fever (>38 degrees C). The mean Pitt bacteremia score (PBS) of the patients was calculated as 6.8, APACHE 2 score as 18.9 and the Charlson co-morbidity index (CCI) as 3.7 (CM: 3.6 vs. NCM: 3.9). Twenty (55.6%) cases in the CM group and 26 cases in the NCM group (542%) (p=0.81) died; 9 cases in the CM group (25%) and 16 cases in the NCM group (33 3%) had treatment failure (P=0.55). Bacteriological eradication was achieved in 20 (55.6%) cases in the CM group and in 36 cases (75%) in the NCM group (P=0.061). Conclusions: No significant difference could be identified between the colistin monotherapy and non-colistin monotherapy options in MDR-AB cases with respect to the results of efficacy and 14-day mortality.
Kaynak
ACTA MEDICA MEDITERRANEACilt
30Sayı
5Koleksiyonlar
- Makale Koleksiyonu [5200]
- Makale Koleksiyonu [5745]
- Öksüz Yayınlar Koleksiyonu - WoS [6162]